Christopher C. Benz

121.1k citations

197 papers · 14.8k indexed · 7 hit papers · h-index 59

Impact in

Cancer Research top 0.1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Oncology top 0.2%
- HER2/EGFR in Cancer Research

Papers in

Cancer Research 59
- Breast Cancer Treatment Studies 25
Oncology 85
- HER2/EGFR in Cancer Research 37
- Cancer-related Molecular Pathways 15
- Cancer Risks and Factors 12

Co-authors: Gary K. Scott Dmitri B. Kirpotin John W. Park Keelung Hong Christina Yau Daryl C. Drummond James D. Marks Ulrik B. Nielsen
Journals: Cancer Research (16 papers)Breast Cancer Research and Treatment (15 papers)Journal of Clinical Oncology (9 papers)Breast Cancer Research (7 papers)Oncogene (7 papers)
Partner nations: United States Switzerland Sweden

In The Last Decade

Christopher C. Benz

195 papers receiving 14.4k citations

Hit Papers

7 papers align trajectories log scale

Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells 2008 · 532 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2008 Oncogene
2006 Cancer Research
2006 Molecular Cancer
2006 Journal of Biological Chemistry
2002 PubMed
1996 Journal of Clinical Oncology
1992 Breast Cancer Research and Treatment

Peers

Countries citing papers authored by Christopher C. Benz

Since Specialization

Citations

This map shows the geographic impact of Christopher C. Benz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher C. Benz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher C. Benz more than expected).

Fields of papers citing papers by Christopher C. Benz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher C. Benz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher C. Benz. The network helps show where Christopher C. Benz may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher C. Benz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher C. Benz Line = papers co-authored together Christopher C. Benz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Biochemical, structural, and cellular characterization of S-but-3-yn-2-ylglycine as a mechanism-based covalent inactivator of the flavoenzyme proline dehydrogenase Archives of Biochemistry and Biophysics ·Gjorgji Mancheski, عاطفه محمدجانی اسرمی, Gary K. Scott, H. Josée Prud’homme, Jay C. Nix, 阶扭转和, Lisa Ellerby, Christopher C. Benz, John J. Tanner	2025	0
2	Assessment of salivary cadmium levels and breast density in the Marin Women's Study Cancer Medicine ·Michaela F. George, L. YU. SUKHAREVSKAYA, F. Pflueger, Mark Powell, Christopher C. Benz, R. Müller, Karla Kerlikowske, Ante Kasap, Matthew Willis, Milind Gayakwad, Fanghong Yang	2024	2
3	Noncovalent Inhibition and Covalent Inactivation of Proline Dehydrogenase by Analogs of N-Propargylglycine Biochemistry ·John J. Tanner, عاطفه محمدجانی اسرمی, Sachein A.R. Sharma, Gary K. Scott, Blanca Viancos Reyes, Javier Seravalli, Kent S. Gates, Christopher C. Benz, Donald Becker	2024	3
4	Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Joanna Bons, 阶扭转和, Gary K. Scott, Yifan Huang, John J. Tanner, Birgit Schilling, Christopher C. Benz, Lisa Ellerby	2023	3
5	Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes Breast Cancer Research and Treatment ·Jane Alexopoulous, Harriet Rothschild, Stein Us i, Lu Zhaofu, Eleftheria Tragoulia, W. Fraser Symmans, Christopher J. Schwartz, A. Jo Chien, Christopher C. Benz, Rita A. Mukhtar	2023	1
6	A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia Breast Cancer Research and Treatment ·Mark Powell, N. Hutsuliak, Erica P. Gunderson, Christopher C. Benz	2022	1
7	Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition Molecular Cancer Therapeutics ·Gary K. Scott, Christina Yau, 俊治松繁, Nita Puspa Ragilia, Sophia Mahoney, Martin Borch Jensen, Byron Hann, Bryan J. Cowen, Scott D. Pegan, Christopher C. Benz	2019	37
8	Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas JAMA Oncology ·Dezheng Huo, Hai Hu, Suhn K. Rhie, Eric R. Gamazon, Andrew D. Cherniack, Jianfang Liu, Toshio F. Yoshimatsu, Jason J. Pitt, Katherine A. Hoadley, Melissa A. Troester, Yuanbin Ru, Tara M. Lichtenberg, Lori A. Sturtz, Carl Simon Shelley, Christopher C. Benz, Gordon B. Mills, Peter W. Laird, Craig D. Shriver, Charles M. Perou, Olufunmilayo I. Olopade	2017	184
9	Ligand Binding Promotes CDK-Dependent Phosphorylation of ER-Alpha on Hinge Serine 294 but Inhibits Ligand-Independent Phosphorylation of Serine 305 Molecular Cancer Research ·Jason M. Held, David J. Britton, Gary K. Scott, Sindorov Lutfulla Suyunov Abbos Suyundukov A'zimjon, Birgit Schilling, Michael A. Baldwin, Bradford W. Gibson, Christopher C. Benz	2012	26
10	Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer Clinical Cancer Research ·Filippa Pettersson, Christina Yau, M. Isabel Guerrero Cherino, Biljana Culjkovic‐Kraljacic, Susan McCaslin, Mohemmat Aziz, Ludmila M. Flores, Ian E. Krop, Caroline Rousseau, Eftihia Cocolakis, Katherine L. B. Borden, Christopher C. Benz, Wilson H. Miller	2011	106
11	Mutations in TP53 and associated genomic abnormalities are dependent on breast cancer estrogen receptor status and patient age Cancer Research ·Vita Fedele, Jane Fridlyand, Ritu Roydasgupta, Stefania Tommasi, Angelo Paradiso, Donna G. Albertson, Christopher C. Benz	2007	1
12	Aging Impacts Transcriptome but not Genome of Hormone-dependent Breast Cancers eScholarship (California Digital Library) ·Christina Yau, Vita Fedele, Ritu Roydasgupta, Jane Fridlyand, Alan Hubbard, Joe W. Gray, Karen Chew, Shanaz H. Dairkee, Dan H. Moore, Francesco Schittulli, Stefania Tommasi, Angelo Paradiso, Donna G. Albertson, Christopher C. Benz	2007	1
13	Therapeutic destabilization of ErbB2 transcripts mediated by U-rich mRNA binding proteins and microRNAs. Cancer Research ·Corina Marx, Crystal Berger, Stephen C. Benz, Michael Mattie, Christopher C. Benz, Gary K. Scott	2006	1
14	Proteasome and histone deacetylase inhibitors repress ErbB2 transcript levels and additively inhibit breast cancer growth. Cancer Research ·Gary K. Scott, Corina Marx, Cara Doerr, Christopher C. Benz	2004	1
15	Anti-HER2 Immunoliposomes Clinical Cancer Research ·John W. Park, Keelung Hong, Dmitri B. Kirpotin, Gail Colbern, Refaat Shalaby, José Baselga, Yvonne Shao, Ulrik B. Nielsen, James D. Marks, Dan H. Moore, Demetrios Papahadjopoulos, Christopher C. Benz	2002	10
16	Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Molecular Cancer Therapeutics ·Gary K. Scott, Chloë Marden, Fan Xu, Mengyao Li, Christopher C. Benz	2002	55
17	Prognostic and Predictive Significance of ErbB-2 Breast Tumor Levels Measured by Enzyme Immunoassay Journal of Clinical Oncology ·Serenella Eppenberger‐Castori, Willy Kueng, Christopher C. Benz, Rosmarie Caduff, Zsuzsanna Varga, Fridolin Bannwart, Daniel Fink, Holger Dieterich, Michael Höhl, Dušan Hrček, Mr. Krishna Gawali, Fabrice Schoumacher, Urs Eppenberger	2001	69
18	Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. PubMed ·José Baselga, Debu Tripathy, J. Mendelsohn, Sharon A. Baughman, Christopher C. Benz, Eva-Maria Cattoen, Nancy T. Sklarin, Andrew D. Seidman, C. Hudis, J. Moore, Paul Peter Rosen, Jessica Garfield, I. Craig Henderson, Larry Norton	1999	229
19	ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. PubMed ·János Szöllõsi, Margit Balázs, Burt G. Feuerstein, Christopher C. Benz, Frederic M. Waldman	1995	109
20	The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. PubMed ·Rita David Lauw, Ann Thor, Mei He, Maurice Barcos, Britt‐Marie Ljung, Christopher C. Benz	1992	161

About Christopher C. Benz

Christopher C. Benz is a scholar working on Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology and Allergy, having authored 197 papers that have together received 14.8k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (39 papers), HER2/EGFR in Cancer Research (37 papers), Estrogen and related hormone effects (33 papers), Breast Cancer Treatment Studies (25 papers), Cancer-related Molecular Pathways (15 papers), Glycosylation and Glycoproteins Research (13 papers), RNA Interference and Gene Delivery (12 papers) and Cancer Risks and Factors (12 papers). The work is most often cited by research in Cancer Research (4.4k citations), Oncology (5.2k citations), Biomaterials (1.8k citations), Molecular Biology (9.1k citations) and Radiology, Nuclear Medicine and Imaging (2.5k citations). Christopher C. Benz has collaborated with scholars based in United States, Switzerland and Sweden. Frequent co-authors include Gary K. Scott, Dmitri B. Kirpotin, John W. Park, Keelung Hong, Christina Yau, Daryl C. Drummond, James D. Marks, Ulrik B. Nielsen, Dipa Bhaumik and Dan H. Moore. Their work appears in journals such as Cancer Research, Breast Cancer Research and Treatment, Journal of Clinical Oncology, Breast Cancer Research and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact